Assignee
BIOGEN IDEC INC
US·174 granted patents·177 pending applications·3,315 citations·filing 1995–2017
Top patents by PatentIndex Score
351 records- 0199US7422739B2Anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Sep 9, 2008·166 cites·13 claims
- 0298US7863419B2Antibodies having altered effector function and methods for making the sameBIOGEN IDEC INC·Filed 2006·Granted Jan 4, 2011·140 cites·88 claims
- 0398US7829092B2Recombinant anti-VLA4 antibody moleculesBIOGEN IDEC INC·Filed 2008·Granted Nov 9, 2010·60 cites·28 claims
- 0498US6896885B2Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphomaBIOGEN IDEC INC·Filed 2001·Granted May 24, 2005·143 cites·29 claims
- 0597US7083785B2Methods of treatment by administering an anti-BCMA antibodyBIOGEN IDEC INC·Filed 2002·Granted Aug 1, 2006·151 cites·18 claims
- 0697US7001598B2Anti-lymphotoxin-beta receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2001·Granted Feb 21, 2006·67 cites·132 claims
- 0796US7951918B2Stabilized polypeptide compositionsBIOGEN IDEC INC·Filed 2007·Granted May 31, 2011·96 cites·52 claims
- 0896US7820161B1Treatment of autoimmune diseasesBIOGEN IDEC INC·Filed 2000·Granted Oct 26, 2010·133 cites·12 claims
- 0996US7381560B2Expression and use of anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Jun 3, 2008·45 cites·10 claims
- 1095US9066984B2Sp35 antibodies and uses thereofBIOGEN IDEC INC·Filed 2013·Granted Jun 30, 2015·26 cites·6 claims
- 1195US7799902B2Receptor coupling agents and compositions thereofBIOGEN IDEC INC·Filed 2006·Granted Sep 21, 2010·29 cites·41 claims
- 1295US7566769B2Tumor necrosis factor related ligandBIOGEN IDEC INC·Filed 2006·Granted Jul 28, 2009·26 cites·27 claims
- 1395US7192585B2CD80 specific antibodiesBIOGEN IDEC INC·Filed 2005·Granted Mar 20, 2007·17 cites·20 claims
- 1495US6875846B2Heterologous polypeptide of the TNF familyBIOGEN IDEC INC·Filed 2002·Granted Apr 5, 2005·95 cites·16 claims
- 1594US8815236B2Method for treating multiple sclerosis and crohn's diseaseBIOGEN IDEC INC·Filed 2012·Granted Aug 26, 2014·22 cites·22 claims
- 1694US7943742B2Anti-αvβ6 antibodies and uses thereofBIOGEN IDEC INC·Filed 2006·Granted May 17, 2011·29 cites·14 claims
- 1794US7838639B2Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptorBIOGEN IDEC INC·Filed 2008·Granted Nov 23, 2010·22 cites·11 claims
- 1894US7655463B2Methods of activating RET receptor tyrosine kinase using neurotrophic factorsBIOGEN IDEC INC·Filed 2008·Granted Feb 2, 2010·24 cites·16 claims
- 1994US7612178B2Anti-IGF-1R antibodies and uses thereofBIOGEN IDEC INC·Filed 2007·Granted Nov 3, 2009·24 cites·16 claims
- 2094US7465449B2Anti-αvβ6 antibodiesBIOGEN IDEC INC·Filed 2003·Granted Dec 16, 2008·71 cites·58 claims
- 2194US7459537B2Anti-lymphotoxin-β receptor antibodies as anti-tumor agentsBIOGEN IDEC INC·Filed 2005·Granted Dec 2, 2008·11 cites·23 claims
- 2294US7358228B2Methods of treating pain using neurotrophic factorsBIOGEN IDEC INC·Filed 2006·Granted Apr 15, 2008·23 cites·29 claims
- 2393US7767687B2Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitorsBIOGEN IDEC INC·Filed 2005·Granted Aug 3, 2010·28 cites·60 claims
- 2493US7744877B2Expression and use of anti-CD20 AntibodiesBIOGEN IDEC INC·Filed 2002·Granted Jun 29, 2010·38 cites·8 claims
- 2593US7579001B2Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disordersBIOGEN IDEC INC·Filed 2006·Granted Aug 25, 2009·17 cites·19 claims
- 2693US7358054B2Antibodies to VLA-1BIOGEN IDEC INC·Filed 2002·Granted Apr 15, 2008·37 cites·25 claims
- 2793US7338658B2Recombinant anti-CD4 antibodies for human therapyBIOGEN IDEC INC·Filed 2002·Granted Mar 4, 2008·36 cites·7 claims
- 2893US7208151B2Tweak receptor agonists as anti-angiogenic agentsBIOGEN IDEC INC·Filed 2001·Granted Apr 24, 2007·36 cites·13 claims
- 2993US7169387B2Antagonists of tweak and of tweak receptor and their use to treat immunological disordersBIOGEN IDEC INC·Filed 2004·Granted Jan 30, 2007·37 cites·18 claims
- 3093US6869605B2BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2001·Granted Mar 22, 2005·75 cites·14 claims
- 3193US6800735B2Interferon-beta fusion proteins and usesBIOGEN IDEC INC·Filed 2001·Granted Oct 5, 2004·65 cites·5 claims
- 3293US6733763B2Induction of cytotoxic T-lymphocyte responsesBIOGEN IDEC INC·Filed 2000·Granted May 11, 2004·39 cites·19 claims
- 3392US7691804B2BAFF receptor (BCMA), an immunoregulatory agentBIOGEN IDEC INC·Filed 2002·Granted Apr 6, 2010·30 cites·5 claims
- 3492US7442370B2Polymer conjugates of mutated neublastinBIOGEN IDEC INC·Filed 2003·Granted Oct 28, 2008·35 cites·68 claims
- 3592US7422899B2Antibodies to the human prolactin receptorBIOGEN IDEC INC·Filed 2006·Granted Sep 9, 2008·47 cites·13 claims
- 3692US7294753B2Method for preparing anti-MIF antibodiesBIOGEN IDEC INC·Filed 2005·Granted Nov 13, 2007·20 cites·12 claims
- 3792US6897044B1Production of tetravalent antibodiesBIOGEN IDEC INC·Filed 1999·Granted May 24, 2005·133 cites·32 claims
- 3891US9353087B2Inhibitors of Bruton's tyrosine kinaseBIOGEN IDEC INC·Filed 2013·Granted May 31, 2016·8 cites·19 claims
- 3991US8821883B2Method of treating B cell cancers by administering truncated BAFF receptorsBIOGEN IDEC INC·Filed 2012·Granted Sep 2, 2014·14 cites·28 claims
- 4091US7910099B2Antibodies to VLA-1BIOGEN IDEC INC·Filed 2010·Granted Mar 22, 2011·12 cites·17 claims
- 4191US7491393B2Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2007·Granted Feb 17, 2009·4 cites·20 claims
- 4291US7175847B1Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4BIOGEN IDEC INC·Filed 2000·Granted Feb 13, 2007·13 cites·45 claims
- 4391US7112421B2Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related theretoBIOGEN IDEC INC·Filed 2001·Granted Sep 26, 2006·25 cites·80 claims
- 4491US7109298B2Tumor necrosis factor related ligandBIOGEN IDEC INC·Filed 2004·Granted Sep 19, 2006·25 cites·10 claims
- 4590US9387237B2Methods of treating a patient having an autoimmune disorder by administering a soluble BCMABIOGEN IDEC INC·Filed 2014·Granted Jul 12, 2016·14 cites·21 claims
- 4690US8894999B2Use of DR6 and p75 antagonists to promote survival of cells of the nervous systemBIOGEN IDEC INC·Filed 2013·Granted Nov 25, 2014·10 cites·14 claims
- 4790US7731963B2TWEAK receptor agonists as anti-angiogenic agentsBIOGEN IDEC INC·Filed 2007·Granted Jun 8, 2010·11 cites·33 claims
- 4890US7695934B2Tumor necrosis factor related ligandBIOGEN IDEC INC·Filed 2006·Granted Apr 13, 2010·11 cites·23 claims
- 4990US7682612B1Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibodyBIOGEN IDEC INC·Filed 1999·Granted Mar 23, 2010·88 cites·60 claims
- 5090US7235360B2Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameBIOGEN IDEC INC·Filed 2004·Granted Jun 26, 2007·24 cites·41 claims
Showing the top 50 of 351 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →